Home > Drug Search >
  • Targets: Mitocliondrial permeability transition pore (mPTP)
  •   > 
Drug Filter
Status:
Approved (2) NDA Filing (2) Phase Ⅲ (4) Phase Ⅱ (14) Phase Ⅰ (10)
Clinical Stage:
Pending (4) Active (12) Discontinued (14)
Company:
Eisai (1) Ipsen (1) Johnson & Johnson (1) Lee's Pharm (1) Merck Sharp & Dohme (1) Millennium Pharmaceutical (1) Mitsubishi Tanabe Pharma (1) Novartis (1) Pfizer (2) Roche (2) Sanofi (2) Santen (1) Takeda (1) UCB (1) Uriach (1) Stason pharma (1) Huons (1) Nanjing Carephar ShengHui Pharmaceutical (1) Nanjing Carephar Medical Technology (2) BeiJing Sciecure Pharmaceutical (1) Institute of Materia Medica Chinese Academy of Medical Sciences (1) Hikma (1) Stealth BioTherapeutics (1) Frontier Biotechnologies (Nanjing) (1) Palau pharma (1) Carephar (2) 60℃ Pharmaceuticals (1) Tianjin FusoGen Pharmaceuticals (1) Akron Molecules (1) Genextra (1) CytoMed (1) Guidotti (1) Alexion (1) Astellas (1) Boehringer Ingelheim (3)
Indication:
Acute coronary syndrome (ACS) (1) Acute lymphoblastic leukaemia (ALL) (1) Allergic rhinitis (AR) (1) Asthma (10) Atopic dermatitis (3) Apnoea (1) Dry eye disease (1) HIV infection (3) Osteoarthritis (OA) (1) Psoriasis (3) Rheumatoid arthritis (RA) (1) Ulcerative colitis (1) Myocardial reperfusion injury (1) Ankylosing Spondylitis (AS) (1) Shoulder periarthritis (1) Chronic heart failure (1) Pain (1) Systemic inflammatory response syndrome (SIRS) (1) Acute ischemic stroke (AIS) (2) Disseminated intravascular coagulation (DIC) (1) Septic shock (1) Gram-negative bacterial infection (1) Mitochondrial myopathies (1) Gout (1) Respiratory syncytial virus infection (1) Dengue fever (1) Cardiac reperfusion injury (1) Blood coagulation disorders (1)
Others:
Sort: Aprv. Year Alphabetical Prev Next
First Prev 1 2 Next Last GO
Recently Viewed Drugs:
Insert title here
Feed-Back To Top
ICP Permit 14047345| Beijing PSB Hai Dian Record 11010802017043 |(京)-经营性-2015-0023(互联网药品信息服务资格证书)
Insert title here
Feed-Back To Top